Boston Scientific acquires U.K. pancreatic cancer firm
File
Boston Scientific's Marlborough headquarters
Marlborough medical device maker Boston Scientific has acquired a privately-held British firm that has developed a device to help treat pancreatic cancer.
The acquisition of EMcision, Ltd., was announced Monday, but the terms were not disclosed.
Both companies released the news Monday morning, with EMcision calling Boston Scientific the world’s premier endoscopic devices company.
EMcision said three of its devices developed by its founder Nagy Habib, have benefited close to 100,000 patients suffering from cancers of the liver, pancreas and bile ducts.
It’s flagship product, the HabibTM EndoHPB probe, was mentioned specifically by Boston Scientific in its press release.
According to Boston Scientific, pancreaticobiliary cancers account for almost 1 million deaths annually worldwide, as those cancers are difficult to remove and only up to 40 percent of those patients are eligible for surgery.
The device helps can improve those patients’ quality of life by draining fluid building up in patients with those types of cancers, Boston Scientific said.
In a statement, Habib said clinical trials showed the device can increase a patient’s chances of survival.
"This new treatment has empowered endoscopists with a very useful device for management of these unfortunate patients with advanced cancer,” Habib said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments